A 45-year-old man with moderate persistent asthma has been stable for a year on medium-dose ICS LABA inhaler therapy. He attends for review and has daytime symptoms less than twice weekly, no night-time symptoms, no limitation of activity, and normal spirometry. What additional non-pharmacologic element should be ensured according to Canadian asthma guidelines?